Table 2. Laboratory findings and treatment of patients

|  | | | **Type 2 Diabetes** | |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Characteristic** | **All patients** (n = 828) | **no** (n = 621) | **yes** (n = 207) | **p value**1 |
| Laboratory findings | WBC (×109/L), Median (IQR) | 11.0 (7.8 – 15.4) | 11.0 (7.7 – 15.3) | 10.7 (8.1 – 16.0) | 0.51 |
|  | Unknown | 46 | 35 | 11 |  |
|  | WBC (×109/L), n (%) |  |  |  | 0.77 |
|  | 4-10 | 300 (38) | 226 (39) | 74 (38) |  |
|  | < 4 | 33 (4.2) | 23 (3.9) | 10 (5.1) |  |
|  | 10 | 449 (57) | 337 (58) | 112 (57) |  |
|  | Unknown | 46 | 35 | 11 |  |
|  | Neutrophils (×109/L), Median (IQR) | 9.2 (6.0 – 13.5) | 9.2 (6.0 – 13.2) | 9.1 (6.4 – 14.3) | 0.47 |
|  | Unknown | 57 | 43 | 14 |  |
|  | Neutrophils (×109/L), n (%) |  |  |  | 0.27 |
|  | <= 6.3 | 270 (33) | 209 (34) | 61 (29) |  |
|  | 6.3 | 558 (67) | 412 (66) | 146 (71) |  |
|  | Lymphocytes (×109/L), Median (IQR) | 0.9 (0.6 – 1.4) | 0.9 (0.6 – 1.4) | 0.9 (0.6 – 1.3) | 0.22 |
|  | Unknown | 57 | 43 | 14 |  |
|  | Lymphocytes (×109/L), n (%) |  |  |  | 0.84 |
|  | = 1 | 407 (49) | 304 (49) | 103 (50) |  |
|  | < 1 | 421 (51) | 317 (51) | 104 (50) |  |
|  | NLR, Median (IQR) | 10.1 (5.4 – 17.3) | 10.0 (5.5 – 16.6) | 10.3 (5.1 – 20.0) | 0.26 |
|  | Unknown | 57 | 43 | 14 |  |
|  | NLR, n (%) |  |  |  | 0.97 |
|  | < 5.86 | 211 (27) | 158 (27) | 53 (27) |  |
|  | = 5.86 | 560 (73) | 420 (73) | 140 (73) |  |
|  | Unknown | 57 | 43 | 14 |  |
|  | Platelets (×109/L), Median (IQR) | 211.0 (101.0 – 272.0) | 210.0 (69.2 – 270.0) | 211.5 (135.0 – 277.0) | 0.26 |
|  | Unknown | 23 | 20 | 3 |  |
|  | Platelets (×109/L), n (%) |  |  |  | 0.16 |
|  | = 125 | 601 (73) | 443 (71) | 158 (76) |  |
|  | < 125 | 227 (27) | 178 (29) | 49 (24) |  |
| Blood gas findings | SaO2 (%), Median (IQR) | 89.0 (82.0 – 94.0) | 89.0 (80.0 – 93.0) | 90.0 (84.0 – 94.0) | 0.063 |
|  | Unknown | 11 | 10 | 1 |  |
|  | SaO2, n (%) |  |  |  | 0.077 |
|  | = 90 | 408 (49) | 295 (48) | 113 (55) |  |
|  | < 90 | 420 (51) | 326 (52) | 94 (45) |  |
|  | FiO2 (%), Median (IQR) | 21.0 (21.0 – 40.0) | 21.0 (21.0 – 40.0) | 21.0 (21.0 – 28.0) | 0.31 |
|  | Unknown | 43 | 33 | 10 |  |
|  | FiO2 (%), n (%) |  |  |  | 0.47 |
|  | 21 (O2 therapy) | 224 (27) | 172 (28) | 52 (25) |  |
|  | 21 | 604 (73) | 449 (72) | 155 (75) |  |
|  | PaO2:FiO2 ratio, Median (IQR) | 175.5 (90.5 – 279.0) | 163.0 (85.4 – 266.0) | 197.0 (108.5 – 310.0) | **0.003** |
|  | Unknown | 66 | 56 | 10 |  |
|  | PaO2:FiO2 ratio, n (%) |  |  |  | 0.10 |
|  | 200 | 387 (47) | 280 (45) | 107 (52) |  |
|  | <= 200 | 441 (53) | 341 (55) | 100 (48) |  |
|  | Calculated PaO2:FiO2 ratio, Median (IQR) | 3.1 (2.0 – 4.0) | 3.0 (1.9 – 3.9) | 3.2 (2.3 – 4.1) | 0.072 |
|  | Unknown | 102 | 84 | 18 |  |
|  | Calculated PaO2:FiO2 ratio, n (%) |  |  |  | 0.067 |
|  | 200 | 102 (12) | 84 (14) | 18 (8.7) |  |
|  | <= 200 | 726 (88) | 537 (86) | 189 (91) |  |
|  | PaO2 (mmHg), Median (IQR) | 72.8 (59.0 – 92.2) | 72.8 (58.4 – 92.0) | 73.1 (61.0 – 95.5) | 0.22 |
|  | Unknown | 67 | 55 | 12 |  |
|  | PaO2, n (%) |  |  |  | 0.19 |
|  | = 60 | 624 (75) | 461 (74) | 163 (79) |  |
|  | < 60 | 204 (25) | 160 (26) | 44 (21) |  |
| Treatment | Corticosteroids, n (%) | 715 (86) | 551 (89) | 164 (79) | **<0.001** |
|  | Anticoagulants, n (%) | 733 (89) | 549 (88) | 184 (89) | 0.85 |
|  | Antimalarials, n (%) | 429 (52) | 319 (51) | 110 (53) | 0.66 |
|  | Pronation, n (%) | 355 (46) | 274 (48) | 81 (42) | 0.19 |
|  | Unknown | 61 | 46 | 15 |  |
| 1Wilcoxon rank sum test; Pearson's Chi-squared test | | | | | |